Cordance Medical

Executive Summary

Cordance Medical is a San Diego-based private medical device company pioneering a non-invasive platform to reversibly open the blood-brain barrier (BBB). Its NeuroAccess system, which recently received FDA Breakthrough Device Designation, aims to enable targeted delivery of therapeutics and diagnostics for major brain diseases such as glioblastoma, Alzheimer's, and Parkinson's. Founded in 2018, the company addresses a critical bottleneck in neurology: the BBB's exclusion of most drugs from the brain. By using focused ultrasound combined with microbubbles, NeuroAccess offers a safe, repeatable method to temporarily disrupt the barrier, potentially transforming treatment paradigms. The Breakthrough Device Designation underscores the FDA's recognition of the technology's promise and accelerates its development pathway. Cordance is now advancing toward first-in-human trials, with the goal of demonstrating safety and preliminary efficacy. The company's platform could also enable new imaging agents for early diagnosis. As a privately held firm, Cordance is likely seeking strategic partnerships and additional funding to support clinical development. The technology's non-invasive nature and broad applicability position it as a potential game-changer in neurotherapeutics, though it remains at an early stage pending clinical validation.

Upcoming Catalysts (preview)

• Q3 2026Initiation of First-in-Human Clinical Trial for NeuroAccess80% success
• Q3 2026Strategic Partnership with a Major Pharmaceutical Company for Drug Delivery Applications50% success
• Q3 2026Series B or C Funding Round to Support Clinical Development75% success